Shannon A. Fairbanks

Bausch & Lomb, Inc. develops, manufactures, and markets eye health products. It offers over-the-counter supplements, eye care products, ophthalmic pharmaceuticals, contact lenses, lens care, ophthalmic surgical devices, and instruments. The company was founded by John Jacob Bausch and Henry Lomb in 1853 and is headquartered in Rochester, NY.

Aronex Pharmaceuticals, Inc. develops proprietary medicines to treat cancer and infectious diseases. The company's products include Nyotran, Atragen, Annamycin, and Zintevir. It is headquartered in The Woodlands, TX.

Oldtech, Inc. was engaged in developing treatments for conditions that affect the back of the eye, including age related macular degeneration (AMD) and diabetic macular edema (DME). The company was headquartered in New York.

Interpath Pharmaceuticals, Inc. develops cancer therapeutics based on liposomal delivery technology for antisense. The company was founded in 2001 by Gabriel Lopez-Berestein and Peter Nielsen and is headquartered in Houston, TX

Lux Biosciences, Inc. provides therapies for treatment of ophthalmic diseases. It develops and commercializes medications for ophthalmic diseases. The company was founded by Ulrich M. Grau, Eddy Anglade, Clarke A. Atwell and Sidney L. Weiss in 2006 and is headquartered in Jersey City, NJ.

Sound Pharmaceuticals Inc. manufactures biopharmaceutical products. It focuses on developing drug treatments for sensori-neural hearing loss. The company was founded by Eric Lynch, Joseph Ashley, Glenn H. Kawasaki and Jonathan Kil in 2001 and is headquartered in Seattle, WA.

Danube Pharmaceuticals, Inc. provides bio pharmaceutical services. It engages in the discovery and development of therapies and devices for ophthalmology. The firm's products include DNB-001, a small molecule for the treatment of glaucoma. The company was founded in 2006 and is headquartered in New York, NY.

Arsenal Capital Management LP (Arsenal Capital) is a private equity subsidiary of Arsenal Capital Group LLC founded in 2000 by Terrence M. Mullen and Jeffrey B. Kovach. The firm is headquartered in New York.

Neurotech Pharmaceuticals, Inc. designs and develops therapeutic systems for retinal diseases. The company was founded in 1995 and is headquartered in Cumberland, RI.

SV Health Investors LLC is a Venture Capital firm, a subsidiary of SV Health Investors LLP founded in 2006. SV Health Investors LLC is headquartered in Boston.

Global Factory, Inc. provides collaborative manufacturing execution systems. The firm's software gather, organize & analyze demand, production & quality data from various sources and monitor key indicators & execute business processes to control, manage & optimize distributed manufacturing operations. The company was founded in 1999 and is headquartered in Santa Clara, CA.

Osmotica Pharmaceutical Corp. provides drug delivery technologies and neurology based therapies. It develops and commercializes a portfolio of products related to central nervous system disorders with a focus in Parkinson's disease and related neurological disorders. The company was founded in 1986 and is headquartered in Bridgewater, GA.

Part of GSK Plc, Novartis Consumer Health, Inc. manufactures and supplies pharmaceutical products. The company is based in Lincoln, NE.

AlloCure, Inc. develops cell therapies for the treatment of kidney diseases. It engages in developing allogeneic mesenchymal stem cell therapy for acute kidney injury. The company was founded in 2008 and is headquartered in Burlington, MA.

Mimetogen Pharmaceuticals, Inc. develops peptidomimetic small molecule drugs against glaucoma and cancer. Its product mimic the effects of neurotrophin proteins that help to maintain the health and growth of cells and tissues found in the eye. Mimetogen provides tyrosine kinase agonists that prevent neuronal death; small molecule tyrosine kinase receptor agonists, which stimulates mucin secretion from conunctival goblet cells; and small molecule neurotrophin mimetics that rescues retinal pigment epithelial cells from oxidative stress-induced apoptosis. The company was founded by Garth Cumberlidge and H. Uri Saragovi in 2005 and is headquartered in Montreal, Canada.

The United States Pharmacopeia engages in manufacturing medicines. It offers dietary supplements, and foods. The company is headquartered in Rockville, MD.

Carter BloodCare engages in the provision of blood components and transfusion services for North, Central and East Texas. It offers collection, testing, and distribution of blood on a local level. It also provides technical support services and educational programs to employees of area healthcare organizations. The company was founded on January 1, 1998 and is headquartered in Bedford, TX.

PanOptica, Inc. operates as a biopharmaceutical company that provides ophthalmology drugs for treatment of eye diseases. The company was founded by Paul G. Chaney and Martin B. Wax in March 2009 and is headquartered in Bernardsville, NJ.

GlySens, Inc. develops glucose monitoring system. It offers GlySens ICGM system, a long continuous glucose monitoring system intends to dramatically improve the lives of people with diabetes. The firm develops testing in clinical trials a novel, long term implant to continuously monitor and transmit blood glucose levels to smart phones and other devices. The company was founded by Joseph Y. Lucisano and David A. Gough in 1998 and is headquartered in San Diego, CA.

Imagen Biotech, Inc. develops therapeutics for sight-threatening diseases. The firm specializes in personalized chemotherapy, medicine, high content screening, cell biology and contract research. The company was founded by David R. Guyer and Matthew Feinsod in 2011 and is headquartered in New York, NY.

iSTAR Medical SA develops innovative ophthalmic implants. Its products include MINIject, STARflo and STAR Material. The company was founded by Michel Alvarez in 2011 and is headquartered in Wavre, Belgium.

Lipomedix Pharmaceuticals Ltd. engages in the development of cancer therapy based on liposome delivery. It offers Promitil®, a proprietary formulation of a lipid-based pro-drug of MMC (MLP) which enables efficient delivery and release of active MMC to tumors in vivo. The company was founded by Alberto Gabizon and Rami Kremien and is headquartered in Jerusalem, Israel.

ColubrisMX, Inc. engages in the provision of healthcare services. The company was founded by Daniel H. Kim in March 2017 and is headquartered in Houston, TX.

Maxwell Biosciences, Inc. operates as biotechnology company for optimizing cognitive performance and health span. The company was founded by Joshua McClure and Annelise Barron in 2016 and is headquartered in Austin, TX.

Visus Therapeutics, Inc. is a clinical stage biopharmaceutical company that focuses on developing multi-targeted ophthalmic therapeutics for the front and back of the eye. The company is based in Seattle, WA and has subsidiaries in the United States. The company is developing novel, pupil-modulating therapeutics designed to correct the loss of near vision associated with presbyopia. In parallel, Visus is advancing its pipeline of early-stage ophthalmic drug candidates engineered to preserve and restore visual function associated with the leading causes of vision loss including cataract and presbyopia, ocular surface and corneal disease, glaucoma, and age-related macular degeneration. The company was founded by Benjamin Scot Bergo, Rhett M. Schiffman, and Benjamin Scot Bergo has been the CEO since incorporation.

Tenpoint Therapeutics Ltd. is a British biotechnology company that specializes in developing engineered cell-based therapies and in vivo reprogramming to restore vision for individuals with degenerative ocular diseases. The company is based in Cambridge, UK and was founded in 2020. Tenpoint Therapeutics brings together experts who are shaping the regenerative ocular medicine revolution and the technologies that are driving it. The company's focus is on replacing diseased cells with healthy ones to permanently restore vision. Eddy Anglade has been the CEO of the company since 2023.

Eyebiotech Ltd. is a British clinical stage ophthalmology company that treats patients with sight-threatening diseases. The company is based in London, UK. Eyebiotech was founded in 2021 by David R. Guyer and Anthony P. Adamis. David R. Guyer has been the CEO since 2021.